Drug intelligence / Profile preview

dronabinol + ondansetron

Development stage
Phase 3
Lead developer
Abbott
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

Dronabinol + ondansetron is a combination therapy used primarily for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (THC), the principal psychoactive component of cannabis. It acts as an agonist at cannabinoid receptors (CB1 and CB2), exerting antiemetic effects by modulating neurotransmitter release in the central nervous system[4][6]. Ondansetron is a selective serotonin 5-HT3 receptor antagonist that blocks serotonin both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone, thereby preventing nausea and vomiting associated with chemotherapy or surgery[5]. Clinical studies have shown that both agents are effective individually for CINV; however, their combination does not provide significant additional benefit over monotherapy with either agent alone[1][3][6]. Both drugs are generally well tolerated when used together.

Other names
delta-9-tetrahydrocannabinoldelta9-tetrahydrocannabinoldelta 9-tetrahydrocannabinolTHC
02

Targets

HTR3A (5-hydroxytryptamine receptor 3A)CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on dronabinol + ondansetron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dronabinol + ondansetron.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call